RU2008141076A - Use of therapeutic human albumin for the manufacture of a medicament for treating patients suffering from cognitive disorders - Google Patents

Use of therapeutic human albumin for the manufacture of a medicament for treating patients suffering from cognitive disorders

Info

Publication number
RU2008141076A
RU2008141076A RU2008141076A RU2008141076A RU2008141076A RU 2008141076 A RU2008141076 A RU 2008141076A RU 2008141076 A RU2008141076 A RU 2008141076A RU 2008141076 A RU2008141076 A RU 2008141076A RU 2008141076 A RU2008141076 A RU 2008141076A
Authority
RU
Grant status
Application
Patent type
Prior art keywords
use according
medicament
albumin
use
vol
Prior art date
Application number
RU2008141076A
Other languages
Russian (ru)
Other versions
RU2414925C2 (en )
Inventor
РОУРА Виктор ГРИФОЛЬС (ES)
РОУРА Виктор ГРИФОЛЬС
Original Assignee
Грифольс, С.А. (Es)
Грифольс, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins

Abstract

1. Применение человеческого альбумина для изготовления лекарственного средства для лечения пациентов, страдающих когнитивными расстройствами или обладающих риском их развития, независимо от содержания Аβ в крови пациента. 1. Use of human albumin for the manufacture of a medicament for treating patients suffering from cognitive disorders or risk having their development, regardless of the content Ap in the patient's blood. ! ! 2. Применение по п.1, при котором это лекарственное средство находится в форме раствора для плазмафильтрации. 2. Use according to claim 1, wherein the medicament is in the form of solution for plasma exchange. ! ! 3. Применение по п.1, при котором это лекарственное средство находится в форме раствора для внутривенного применения. 3. Use according to claim 1, wherein the medicament is in the form of a solution for intravenous use. ! ! 4. Применение по п.1, при котором альбумин исходно имеет концентрацию от 4% (мас./об.) до 25% (мас./об.). 4. Use according to claim 1, wherein the initial albumin has a concentration of 4% (wt. / Vol.) To 25% (wt. / Vol.). ! ! 5. Применение по п.4, при котором применяемый альбумин имеет концентрацию от 4,5% (мас./об.) до 5,5% (мас./об.). 5. Use according to claim 4, in which the albumin used has a concentration of 4.5% (wt. / Vol.) To 5.5% (wt. / Vol.). ! ! 6. Применение по п.1, при котором применяемый альбумин обладает лучшей связывающей способностью по сравнению с терапевтическим препаратом альбумина, изготовленным в соответствии с Европейской Фармакопеей. 6. Use according to claim 1, wherein the albumin used has a better binding ability as compared to a therapeutic drug albumin made in accordance with the European Pharmacopoeia. ! ! 7. Применение по любому из пп.1-6, при котором когнитивное расстройство представляет собой болезнь Альцгеймера. 7. Use according to any one of claims 1-6, wherein the cognitive disorder is Alzheimer's disease.

Claims (7)

  1. 1. Применение человеческого альбумина для изготовления лекарственного средства для лечения пациентов, страдающих когнитивными расстройствами или обладающих риском их развития, независимо от содержания Аβ в крови пациента. 1. Use of human albumin for the manufacture of a medicament for treating patients suffering from cognitive disorders or risk having their development, regardless of the content Ap in the patient's blood.
  2. 2. Применение по п.1, при котором это лекарственное средство находится в форме раствора для плазмафильтрации. 2. Use according to claim 1, wherein the medicament is in the form of solution for plasma exchange.
  3. 3. Применение по п.1, при котором это лекарственное средство находится в форме раствора для внутривенного применения. 3. Use according to claim 1, wherein the medicament is in the form of a solution for intravenous use.
  4. 4. Применение по п.1, при котором альбумин исходно имеет концентрацию от 4% (мас./об.) до 25% (мас./об.). 4. Use according to claim 1, wherein the initial albumin has a concentration of 4% (wt. / Vol.) To 25% (wt. / Vol.).
  5. 5. Применение по п.4, при котором применяемый альбумин имеет концентрацию от 4,5% (мас./об.) до 5,5% (мас./об.). 5. Use according to claim 4, in which the albumin used has a concentration of 4.5% (wt. / Vol.) To 5.5% (wt. / Vol.).
  6. 6. Применение по п.1, при котором применяемый альбумин обладает лучшей связывающей способностью по сравнению с терапевтическим препаратом альбумина, изготовленным в соответствии с Европейской Фармакопеей. 6. Use according to claim 1, wherein the albumin used has a better binding ability as compared to a therapeutic drug albumin made in accordance with the European Pharmacopoeia.
  7. 7. Применение по любому из пп.1-6, при котором когнитивное расстройство представляет собой болезнь Альцгеймера. 7. Use according to any one of claims 1-6, wherein the cognitive disorder is Alzheimer's disease.
RU2008141076A 2007-10-26 2008-10-17 Application of therapeutic human albumin for preparing drug for treating patients suffering cognitive disorders RU2414925C2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES200702831 2007-10-26
ES200702831A ES2332846B1 (en) 2007-10-26 2007-10-26 Use of therapeutic human albumin for the preparation of a medicament for the treatment of patients with cognitive disorders.

Publications (2)

Publication Number Publication Date
RU2008141076A true true RU2008141076A (en) 2010-04-27
RU2414925C2 RU2414925C2 (en) 2011-03-27

Family

ID=40583637

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008141076A RU2414925C2 (en) 2007-10-26 2008-10-17 Application of therapeutic human albumin for preparing drug for treating patients suffering cognitive disorders

Country Status (7)

Country Link
US (1) US7851446B2 (en)
EP (1) EP2111868B1 (en)
JP (1) JP5437619B2 (en)
CN (1) CN101417123B (en)
CA (1) CA2641830C (en)
ES (2) ES2332846B1 (en)
RU (1) RU2414925C2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10112000B2 (en) 2010-07-08 2018-10-30 Asahi Kasei Medical Co., Ltd. Method for reducing amyloid beta concentration in blood
WO2018034712A1 (en) * 2016-08-18 2018-02-22 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612137A1 (en) 1986-04-10 1987-10-15 Biotest Pharma Gmbh Sterile plasma-exchange medium
US5112298A (en) 1990-06-25 1992-05-12 Baxter International Inc. Apheresis method and device
US5178603A (en) 1990-07-24 1993-01-12 Baxter International, Inc. Blood extraction and reinfusion flow control system and method
US6627151B1 (en) * 1997-06-13 2003-09-30 Helmut Borberg Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion
US7695903B2 (en) 2000-05-23 2010-04-13 The University Of Southern California Low-density lipoprotein receptor related protein-1 (LRP-1)in clearance of alzheimer's amyloid-beta peptide from the central nervous system
WO2002078670A1 (en) * 2001-03-02 2002-10-10 Neuron Therapeutics, Inc. Neuroprotectants formulations and methods
EP2210892A3 (en) 2002-10-04 2010-10-27 Prana Biotechnology Limited Neurologically-active compounds
EP1651195A4 (en) 2003-07-11 2007-10-03 Myriad Genetics Inc Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
US20050182044A1 (en) 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
US7436304B1 (en) 2005-07-19 2008-10-14 Visible Assets, Inc Evidence tracking

Also Published As

Publication number Publication date Type
CN101417123B (en) 2012-06-27 grant
CA2641830A1 (en) 2009-04-26 application
JP2009108059A (en) 2009-05-21 application
ES2332846A1 (en) 2010-02-12 application
ES2428698T3 (en) 2013-11-08 grant
EP2111868B1 (en) 2013-08-21 grant
RU2414925C2 (en) 2011-03-27 grant
US7851446B2 (en) 2010-12-14 grant
ES2332846B1 (en) 2010-07-08 grant
EP2111868A1 (en) 2009-10-28 application
CN101417123A (en) 2009-04-29 application
JP5437619B2 (en) 2014-03-12 grant
CA2641830C (en) 2013-07-16 grant
US20090111740A1 (en) 2009-04-30 application

Similar Documents

Publication Publication Date Title
Rawal Analgesia for day-case surgery
Bianconi et al. The pharmacokinetics and efficacy of ropivacaine continuous wound instillation after spine fusion surgery
White et al. Does the use of electroencephalographic bispectral index or auditory evoked potential index monitoring facilitate recovery after desflurane anesthesia in the ambulatory setting?
HERD et al. Ototoxicity of topical neomycin augmented by dimethyl sulfoxide
Yoo et al. Treatment of pregabalin toxicity by hemodialysis in a patient with kidney failure
CA2495454A1 (en) Pharmaceutical compositions for inhalation containing a new anticholinergic in conjunction with corticosteroids and betamimetics
Lader Antianxiety drugs: Clinical pharmacology and therapeutic use
Konstantopoulos et al. Sevoflurane versus propofol anesthesia in patients undergoing lumbar spondylodesis: a randomized trial
Mohta et al. Continuous paravertebral infusion of ropivacaine with or without fentanyl for pain relief in unilateral multiple fractured ribs
Lee et al. Comparison of palonosetron, granisetron, and ramosetron for the prevention of postoperative nausea and vomiting after laparoscopic gynecologic surgery: a prospective randomized trial
CN102228525A (en) Traditional Chinese medicine for treating cardio-cerebral vascular stagnation
CN1443563A (en) Huoluo oil
CN102335465A (en) Blood perfusion device for treating uremia
Aghadavoudi et al. Comparison of two modes of ventilation after fast-track cardiac surgery: Adaptive support ventilation versus synchronized intermittent mandatory ventilation
Cinotti et al. Reinforcing Anesthesia in Cataract Surgery: Report on a New Technique
Ramkiran et al. BIS targeted propofol sparing effects of dexmedetomidine versus ketamine in outpatient ERCP: a prospective randomised controlled trial
Kromdijk et al. Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique
CN1970040A (en) Chinese medicine for treating hypertension, diabetes and coronary heart disease caused by atherosclerosis
Karnad et al. Continuous renal replacement therapy may aid recovery after cardiac arrest
CN201578742U (en) Uterine cavity implanter for curing endometritis and salpingitis
CN202136456U (en) Orthopedic fixing splint
Kim et al. The effects of oral atenolol or enalapril premedication on blood loss and hypotensive anesthesia in orthognathic surgery
CN202426693U (en) Fixed toe separator
CN2633287Y (en) Medicinal nasal obstruction
RU2009122281A (en) The agent for treating diseases in veterinary medicine based on the phosphonium salt